Titlebook: Clinical Management of Acute Lymphoblastic Leukemia; From Bench to Bedsid Mark R. Litzow,Elizabeth A. Raetz Book 2022 Springer Nature Switz

Washington

書目名稱Clinical Management of Acute Lymphoblastic Leukemia影響因子(影響力)




書目名稱Clinical Management of Acute Lymphoblastic Leukemia影響因子(影響力)學(xué)科排名




書目名稱Clinical Management of Acute Lymphoblastic Leukemia網(wǎng)絡(luò)公開(kāi)度




書目名稱Clinical Management of Acute Lymphoblastic Leukemia網(wǎng)絡(luò)公開(kāi)度學(xué)科排名




書目名稱Clinical Management of Acute Lymphoblastic Leukemia被引頻次




書目名稱Clinical Management of Acute Lymphoblastic Leukemia被引頻次學(xué)科排名




書目名稱Clinical Management of Acute Lymphoblastic Leukemia年度引用




書目名稱Clinical Management of Acute Lymphoblastic Leukemia年度引用學(xué)科排名




書目名稱Clinical Management of Acute Lymphoblastic Leukemia讀者反饋




書目名稱Clinical Management of Acute Lymphoblastic Leukemia讀者反饋學(xué)科排名

AWRY

,La régression linéaire multiple,g germline variants that predispose to familial and sporadic ALL, the constellations of genetic changes that define each subtype, and the relationship between genetic variegation, clonal diversity and relapse in ALL. Many of these genetic alterations are of clinical importance as they refine diagnos

amyloid

Pierre-André Cornillon,Eric Matzner-L?bera second remission followed by allogeneic hematopoietic stem cell transplantation (HSCT). In recent years, the advent of targeted therapies such as monoclonal antibodies (mAbs) and chimeric antigen receptor (CAR)-T cells, a better understanding of prognostic genomic markers, refined techniques for d

極為憤怒

Virtues

GLARE

GLARE

,Theorie ergodique de l’equirepartition,ys and next-generation sequencing technologies, have identified a number of recurrent lesions that can be grouped into several targetable pathways, including Notch, Jak/Stat, MAPK/Ras, PI3K/Akt/mTOR, and cyclin-dependent kinase signaling. Other newer methods to target T-ALL include the use of epigen

Banquet

,Theorie ergodique de l’equirepartition,icities, the role of consolidation therapy following CAR T cell therapy, and the development of new cellular products to overcome observed mechanisms of resistance. Here we will review the relevant progress to date with the use of CAR T cells against B-ALL and discuss the limitations and future dire

不要不誠(chéng)實(shí)

Molecular Pathways and Targets in B-Cell Progenitor Acute Lymphoblastic Leukemiag germline variants that predispose to familial and sporadic ALL, the constellations of genetic changes that define each subtype, and the relationship between genetic variegation, clonal diversity and relapse in ALL. Many of these genetic alterations are of clinical importance as they refine diagnos

Aggrandize